New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide.

ABSTRACT: Daily 20-μg and once-weekly 56.5-μg teriparatide (parathyroid hormone 1-34) treatment regimens increase bone mineral density (BMD) and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on r

SUBMITTER: Tanaka S 

PROVIDER: S-EPMC4472137 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature